Betanin protects against diabetic retinal damage via the inhibition of NF-κB/NLRP3/VEGF axis: Insights from network pharmacology and experimental studies
Experimental Eye Research · مجلد 264 · 110863-110863
Research outputs
مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.
50 مُخرَج نتائج البحث عن «Neuroprotection»
Experimental Eye Research · مجلد 264 · 110863-110863
Frontiers in Aging Neuroscience · مجلد 18
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.
Current Bioactive Compounds · مجلد 22
Introduction: Neurodegenerative diseases present major challenges in biomedical research, and identifying natural sources with potential cytoprotective effects remains an important exploratory goal. This study investigates the cytoprotective properties of Fagonia arabica in human neuroblastoma (SK‑N‑SH) cells exposed to oxidative and neurotoxic stressors. Methods: he dried plant material was subjected to a sequential solvent extraction method. The antioxidant and anti-inflammatory activity was assessed by standard procedures. Cytotoxicity was assessed in L929 fibroblasts, and in vitro neuroprotective effects were examined in SK‑N‑SH neuroblastoma cells exposed to trimethyltin (TMT). The GCMS analysis identified the phytocompounds, and an in silico study was performed using molecular docking against targeted proteins. Results: The phytochemical analysis identified phytochemicals like flavonoids, alkaloids, and phenols. In silico analysis indicated that several detected phytochemicals showed notable binding affinity toward targets associated with oxidative stress and inflammation. The extract exhibited anti-inflammatory effects in protein denaturation (IC50 141.88 µg/mL) and COX-2 inhibition assays (IC50 53.65 µg/mL), along with antioxidant activity via DPPH scavenging (IC50 138.14 µg/mL). Cytotoxicity testing demonstrated low toxicity in L929 cells (IC50 = 162.43 µg/mL). In the TMT‑injury model, the extract improved SK‑N‑SH cell viability (86.52% at 50 µg/mL), indicating potential cytoprotective activity under oxidative stress conditions. Results: The phytochemical analysis identified phytochemicals like flavonoids, alkaloids, and phenols. In silico analysis indicated that several detected phytochemicals showed notable binding affinity toward targets associated with oxidative stress and inflammation. The extract exhibited anti-inflammatory effects in protein denaturation (IC50 141.88 µg/mL) and COX-2 inhibition assays (IC50 53.65 µg/mL), along with antioxidant activity via DPPH scavenging (IC50 138.14 µg/mL). Cytotoxicity testing demonstrated low toxicity in L929 cells (IC50 = 162.43 µg/mL). In the TMT‑injury model, the extract improved SK‑N‑SH cell viability (86.52% at 50 µg/mL), indicating potential cytoprotective activity under oxidative stress conditions. Discussion: The biological activities of the extract are likely due to its phytochemical constituents, particularly flavonoids and phenolic compounds. The in silico predictions supported the experimental findings of anti-inflammatory and antioxidant activities. The extract also showed low cytotoxicity and demonstrated cytoprotective effects under oxidative stress conditions, suggesting potential therapeutic value, warranting further investigation into its mechanisms and pharmacological applications. Conclusion: Fagonia arabica demonstrated antioxidant, anti-inflammatory, and preliminary neuroprotective effects at the cellular level. While these findings support the plant’s potential as a source of bioactive compounds with neuroprotective potential, the study does not directly model the complex pathology of Alzheimer’s disease. Further investigations using disease-relevant models are required to clarify its therapeutic relevance
Frontiers in Aging Neuroscience · مجلد 18 · 1742343-1742343
Background: Sleep is a fundamental biological process essential for maintaining mental, emotional, and physical health. Chronic sleep deprivation (SD), particularly in aging, is associated with oxidative stress, neuroinflammation, apoptosis, and cognitive and behavioral impairments. Oxytocin, a hypothalamic neuropeptide with reported antioxidant and anti-inflammatory properties, may modulate stress-related pathways; however, its role in mitigating SD-induced brain alterations remains unclear. This study investigated whether peripheral oxytocin administration influences brain and behavioral changes induced by chronic SD in aged rats. Methods: Male Sprague Dawley rats aged 20-24 months were divided into four groups: control, oxytocin-treated, SD, and SD with oxytocin treatment. Chronic SD was induced using a modified multiple platform method. Behavioral assessments were conducted to evaluate locomotor and exploratory activity. Serum cortisol was measured as a systemic stress marker, while brain tissues were analyzed for oxidative stress and inflammatory markers. Gene expression of Psen1 and Htr2a, oxytocin receptor protein levels, and histopathological changes, including gliosis and apoptosis, were also evaluated. Results: Chronic SD resulted in significant impairments in locomotor and exploratory behaviors, elevated serum cortisol levels, and increased oxidative stress and inflammatory markers. SD also altered the expression of Psen1 and Htr2a, reduced oxytocin receptor protein levels, and was associated with histological evidence of gliosis and apoptosis in brain tissues. Peripheral oxytocin administration attenuated many of these SD-induced alterations. However, because oxytocin was administered peripherally and central oxytocin levels or receptor engagement were not directly assessed, the findings cannot be interpreted as definitive evidence of direct central neuroprotection. Conclusion: The results suggest that oxytocin modulates stress responses, oxidative balance, and inflammatory pathways in aged rats subjected to chronic sleep deprivation. Although the precise central mechanisms remain unresolved, these findings support a potential role for oxytocin in mitigating SD-associated pathophysiological changes in aging and warrant further mechanistic studies to clarify its neuroprotective potential.
Tissue and Cell · مجلد 104 (Pt 2) · 103975-103975
Current Opinion in Pharmacology · مجلد 91 · 102676-102676
Neuroscience · مجلد 569 · 161-183
Tissue and Cell · مجلد 94 · 102779-102779
Frontiers in Pharmacology · مجلد 16 · 1622018-1622018
Introduction: Repetitive traumatic brain injury (RTBI) represents a cumulative neurological insult associated with progressive neurodegeneration and limited therapeutic options. In this study, we uniquely evaluate the neuroprotective potential of mesenchymal stem cell (MSC)-derived exosomes in a rat model of RTBI, an area scarcely explored. Methods: RTBI was induced via a controlled mechanical impact to the skull once every day for 5 days. MSC-derived exosomes were administered 24 h after the final insult in two paradigms: a single dose (MSC-Ex1) with 2 weeks of follow-up, and a dual dose (MSC-Ex2) given 1 week apart, with sacrifice 1 week later. Rats were assigned to four groups: control, RTBI, RTBI + MSC-Ex1, and RTBI + MSC-Ex2. Results: MSC-derived exosome regimens comparably restored cognitive performance in the Novel Object Recognition and Y-maze tests. While both treatment paradigms preserved cortical histoarchitecture, the double-dose regimen led to a more pronounced restoration compared to the moderate tissue recovery observed in the single-dose group. Crucially, this work identifies parthanatos inhibition as a novel mechanistic axis for MSC-derived exosomes-mediated neuroprotection. MSC-derived exosomes attenuated excitotoxicity and oxidative stress, quelling the parthanatos cascade by suppressing PARP1, PAR polymers, nuclear AIF and MIF, as well as calpain, key executors of this caspase-independent cell death pathway. Additionally, MSC-derived exosomes normalized cyclophilin B and Hsp70 levels, suggesting their compensatory role in modulating the endogenous stress response. Conclusion: Overall, these findings demonstrate that MSC-derived exosomes counteract RTBI-induced neurodegeneration through multifaceted mechanisms, with parthanatos suppression at the core. Importantly, the dual-dosing regimen conferred no significant benefit over the single dose, highlighting the therapeutic promise of early intervention. This study positions MSC-derived exosomes as a novel, cell-free therapy capable of intercepting RTBI-induced neuropathology by targeting an under recognized form of programmed cell death.
Frontiers in Molecular Biosciences · مجلد 12 · 1621240-1621240
Background and aim: This study investigated the ameliorative effect of Silymarin-nanoliposome (SLNPs) against monosodium glutamate (MSG)-induced cerebellar toxicity, illuminating its impact on motor coordination. Methods: Forty male Wistar albino rats were divided into four groups. Group I (control group): rats received 2 mL of 0.9% NaCl solution; Group II (SLNPs group): rats received SLNPs with a dose of 500 μg/kg bw orally; Group III (MSG group): rats received 3.5 mg/kg bw of MSG intraperitoneally; and Group IV: rats received combined treatment of MSG + SLNPs for ten consecutive days. Results: MSG-induced cerebellar motor incoordination is represented by increased falls in rats and decreased tow latency spent on the rotarod test. Moreover, MSG altered cerebellar histological structure and significantly (p < 0.05) decreased antioxidant system activity and protein levels of phosphorylated phosphoinositide 3-kinases (p-PI3K), phosphorylated protein kinase B (p-AKT), and brain-derived neurotrophic factor (BDNF). Additionally, there is a decrease in the immunoexpression of nuclear factor erythroid 2-related factor 2 (Nrf2) and gene expression of heme oxygenase-1 (HO-1), tropomyosin receptor kinase B (TrkB), and anti-apoptotic B-cell lymphoma-2 (Bcl-2), alongside an increase in the sera and protein levels of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), immunoexpression of glial fibrillary acidic protein (GFAP), nuclear factor kabba beta (NF-κB), caspase-3, and gene expression of proapoptotic Bax. However, SLNPs prevented MSG-induced cerebellar toxicity, improving motor coordination and morphological structure by enhancing antioxidant, anti-inflammatory, and anti-apoptotic activity by stimulating the PI3K/AKT pathway. Conclusion: The current study indicated that SLNP administration protects against MSG-induced cerebellar damage, preventing cerebellar oxidative stress, inflammation, and apoptosis, opening the door to examining its clinical use in preventing MSG-induced cerebellar motor incoordination.
Tissue and Cell · مجلد 94 · 102832-102832
Journal of Food Biochemistry · مجلد 2025 (1)
Ethnopharmacological Relevance: Bisphenol A (BPA) is a widely used chemical, particularly in producing epoxy resins and polycarbonate plastics, which can contaminate food and water sources. Even low levels of BPA exposure have been associated with negative impacts on neural development, leading to neurotoxicity. Purple carrots, known for their health‐promoting properties, are rich in bioactive compounds such as polyphenols. Materials and Methods: This study aimed to evaluate the neuroprotective effects of purple carrot extract in mitigating BPA‐induced neurotoxicity in albino rats. Forty albino rats were divided into four groups: Group I (control) received water and a standard diet. Group II (BPA group) was orally administered 50 mg/kg body weight of BPA dissolved in 1 mL of olive oil daily for 30 days. Group III received 400 mg/kg of purple carrot extract along with 50 mg/kg of BPA daily. Group IV received 800 mg/kg of purple carrot extract along with 50 mg/kg of BPA daily, following the same 30‐day oral administration protocol. Results: The results showed that treatment with purple carrot extract increased serum levels of critical neurotransmitters, including serotonin, dopamine, acetylcholine, acetylcholineesterase, and gamma‐aminobutyric acid (GABA). Additionally, brain tissue analysis revealed elevated activity of antioxidant enzymes, such as catalase (CAT) and superoxide dismutase (SOD), in response to extract administration. Conversely, the extract significantly reduced levels of malondialdehyde (MDA), α‐tumor necrosis factor (α‐TNF), and interleukin‐6 (IL‐6) in brain tissues compared to the BPA‐only group. These results indicate that purple carrot extract regulates genes related to oxidative stress, inflammation, and apoptosis in a dose‐dependent manner during BPA‐induced neurotoxicity. At a dose of 400 mg/kg, the extract increased the expression of antioxidant genes like Nrf2 and HO‐1 while reducing the pro‐apoptotic marker Bax. At the higher dose of 800 mg/kg, these protective effects were even more pronounced, leading to enhanced neuroprotection through increased antioxidant and antiapoptotic gene expression and reduced inflammation, mainly through the MAPK pathway. Conclusion: The study demonstrates that purple carrot extract reduces BPA‐induced neurotoxicity in rats by enhancing antioxidants, neurotransmitters, and anti‐inflammatory responses, suggesting natural protection against BPA‐related neural damage.
Tissue and Cell · مجلد 98 · 103190-103190
Tissue and Cell · مجلد 98 · 103184-103184
Brain Disorders · مجلد 18 · 100235-100235
• The pathogenesis of the disease multiple sclerosis (MS) is not well understood, but there are several existing theories. • MS is a demyelinating disease affecting the neurons of the central nervous system due to an immune-mediated process and leading to different neurological manifestations. • Its etiology is due to a network of interactions between genetic, immune, and environmental factors. • This comprehensive review paper offers recent insight through MS’s clinical manifestations, epidemiology, pathogenesis, and therapies, shedding light on some futuristic treatments for this disease. Multiple sclerosis (MS) is a chronic, immune-mediated neurological disorder that continues to challenge both researchers and clinicians. While advances in understanding its pathophysiology have led to improved disease-modifying therapies, these treatments primarily focus on immunosuppression and relapse prevention, leaving progressive forms of MS with limited options. Neurodegeneration, myelin loss, and long-term disability remain major hurdles, underscoring the urgent need for therapies that go beyond symptom management to actively repair damage and alter disease progression. With emerging breakthroughs in regenerative medicine, including stem cell-based therapies and novel immune-targeting treatments, we are entering a new era of MS research that prioritizes neuroprotection and repair. This review explores the latest insights into MS classification, pathogenesis, and treatment approaches, with a particular focus on cutting-edge therapies that hold the potential to shift MS care from disease suppression to long-term recovery. By bridging research and clinical application, this study aims to highlight the most promising avenues for future innovation and improved patient outcomes.